Common use of Publications Regarding Results of the Research Program Clause in Contracts

Publications Regarding Results of the Research Program. Neither Party may publish, present or announce results of the Research Programs or Development of ADCs or Licensed Products hereunder either orally or in writing (a “Publication”) without complying with the provisions of this Section 7.5. A Party wishing to make a Publication will provide the other Party with a copy of the proposed Publication. The other Party will have [***] days from receipt of a proposed Publication to provide comments or proposed changes to the publishing Party. The publishing Party will take into account the comments or proposed changes made by the other Party on any Publication and will agree to designate employees or others acting on behalf of the other Party as co-authors on any Publication describing results to which such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential Information or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties will be delayed for such period as may be reasonably necessary for deleting any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication), or the drafting and filing of a patent application covering or claiming such invention, provided such additional period will not exceed [***] days from the date the publishing Party first provided the proposed Publication to the other Party. Notwithstanding anything to the contrary in the foregoing, with respect to any Publications by investigators, such materials will be subject to review by Mersana under this Section 7.5 only to the extent that Merck has the right to review such Publications, and Merck will use Commercially Reasonable Efforts to obtain such right. [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

Publications Regarding Results of the Research Program. Neither Party may publish, or otherwise publicly present or announce results of the Research Programs or Development of ADCs or Licensed Products hereunder either orally or in writing (a “Publication”) without complying with the provisions of this Section 7.59.5. A Party wishing to make a Publication will provide the other Party with a copy of the proposed Publication. The other Party will shall have [***] days Business Days from receipt of a proposed Publication to provide comments or proposed changes to the publishing Party. The publishing Party will shall take into account the comments or proposed changes made by the other Party on any Publication and will shall agree to designate employees or others acting on behalf of the other Party as co-authors on any [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Publication describing results to which such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential Information or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties will shall be delayed for such period as may be reasonably necessary for deleting any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication), or the drafting and filing of a patent application covering or claiming such invention, provided such additional period will shall not exceed [***] days Business Days from the date the publishing Party first provided the proposed Publication to the other Party. Notwithstanding anything to the contrary in the foregoing, with respect to any Publications by investigatorsinvestigators or other Third Parties, such materials will shall be subject to review by Mersana under this Section 7.5 9.5 only to the extent that Merck Licensee has the right to review such Publications, and Merck will use ability (after using Commercially Reasonable Efforts Efforts) to obtain such rightdo so. [***] Portions Without limitation of this exhibit have been redacted pursuant the foregoing, MTI’s rights to make any Publication will be limited to the results of a confidential treatment request. An unredacted version Research Program and after exercise of this exhibit has been filed separately an Option hereunder, MTI shall not make any Publication with respect to the Commissionapplicable Research Program without Licensee’s prior written consent.

Publications Regarding Results of the Research Program. Neither Party may publish, present or announce results of the Research Programs or Development of ADCs or Licensed Products hereunder Program either orally or in writing writing, or use the other Party’s name or trademarks in any publication, research report or study (each, a “Publication”) without complying with the provisions of this Section 7.58.5. A Any Party wishing to make a Publication will provide shall send notice to the other Party. No Publication shall contain any Confidential Information of the other Party with a copy without the consent and approval of the proposed Publicationother Party, which may be granted or withheld in the sole discretion of a Party. The other Party will shall have [***] days from receipt of a proposed Publication to provide comments or and/or proposed changes to the publishing Party. The publishing Party will shall take into account the comments or and/or proposed changes made by the other Party on any Publication and will shall agree to designate employees or others acting on behalf of the other Party as co-authors on any Publication describing results to which such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential Information or and/or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties will shall be delayed for such period as may be reasonably necessary for deleting [***] any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication), or and/or the drafting and filing of a patent application covering or claiming such invention, provided such additional period will shall not exceed [***] days from the date the publishing Party first provided the proposed Publication to the other Party. Notwithstanding anything to In the contrary in the foregoing, with respect to event of any Publications by investigators, such materials will be subject to review by Mersana disagreement under this Section 7.5 only to 8.5, any dispute shall be resolved in the extent that Merck has the right to review such Publications, and Merck will use Commercially Reasonable Efforts to obtain such right. [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commissionmanner specified in Section 19.3.

Publications Regarding Results of the Research Program. Neither Party may publish, present or announce results of the Research Programs or Development of ADCs or Licensed Products hereunder either orally or in writing (a “Publication”) without complying with the provisions of this Section 7.5. A Party wishing to make a Publication will provide the other Party with a copy of the proposed Publication. The other Party will have [***] days from receipt of a proposed Publication to provide comments or proposed changes to the publishing Party. The publishing Party will take into account the comments or proposed changes made by the other Party on any Publication and will agree to designate employees or others acting on behalf of the other Party as co-authors on any Publication describing results to which such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential Information or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties will be delayed for such period as may be reasonably necessary for deleting any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication), or the drafting and filing of a patent application covering or claiming such invention, provided such additional period will not exceed [***] days from the date the publishing Party first provided the proposed Publication to the other Party. Notwithstanding anything to the contrary in the foregoing, with respect to any Publications by investigators, such materials will be subject to review by Mersana under this Section 7.5 only to the extent that Merck has the right to review such Publications, and Merck will use Commercially Reasonable Efforts to obtain such right. [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

Publications Regarding Results of the Research Program. Neither Party may publish, present or announce results of the Research Programs or Development of Licensed ADCs or Licensed Products hereunder either orally or in writing (a “Publication”) without complying with the provisions of this Section 7.58.6. A Party wishing to make a Publication will provide the other Party with a copy of the proposed Publication. The other Party will have [***] days from receipt of a proposed Publication to provide comments or proposed changes to the publishing Party. The publishing Party will take into good faith account the comments or proposed changes made by the other Party on any Publication and will agree to designate employees or others acting on behalf of the other Party as co-authors on any Publication describing results to which such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential Information or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties will be delayed for such period as may be reasonably necessary for deleting any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication), or the drafting and filing of a patent application covering or claiming such invention, provided such additional period will not exceed [***] days from the date the publishing Party first provided the proposed Publication to the other Party. Notwithstanding anything to the contrary in the foregoing, with respect to any Publications by investigators, such materials will be subject to review by Mersana Xxxxxxx under this Section 7.5 8.6 only to the extent that Merck ATSA has the right to review such Publications, and Merck XXXX will use Commercially Reasonable Efforts to obtain such right. [***] Portions For clarity, Mersana may make publications, presentations and announcements with respect to the Mersana Technology and Mersana IP without the prior written consent of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately ATSA and without complying with the Commissionprocess outlined in this Section 8.6; provided that, such publication, presentation or announcement does not include the results of the Research Programs or Development of Licensed ADCs or Licensed Products or other Confidential Information of ATSA hereunder.

Publications Regarding Results of the Research Program. Neither Party may publish, present or announce results of the Research Programs or Development of ADCs or Licensed Products hereunder Program either orally or in writing (a “Publication”) without complying with the provisions of this Section 7.5. A Party wishing to make a Publication will provide the other Party with a copy of the proposed Publication8.4. The other Party will shall [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. have [***] days from receipt of a proposed Publication to provide comments or and/or proposed changes to the publishing Party. The publishing Party will shall take into account the comments or and/or proposed changes made by the other Party on any Publication and will shall agree to designate employees or others acting on behalf of the other Party as co-authors on any Publication describing results to which such persons have contributed in accordance with standards applicable to authorship of scientific publications. If the other Party reasonably determines that the Publication would entail the public disclosure of such Party’s Confidential Information or and/or of a patentable invention upon which a patent application should be filed prior to any such disclosure, submission of the concerned Publication to Third Parties will Parties, the confidential information shall be deleted and publication shall be delayed for such period as may be reasonably necessary for deleting any such Confidential Information of the other Party (if the other Party has requested deletion thereof from the proposed Publication)) to be deleted, or and/or the drafting and filing of a patent application covering or claiming such invention, provided such additional period will shall not exceed [***] days from the date the publishing Party first provided the proposed Publication to the other Party. Notwithstanding anything to the contrary in the foregoing, with respect to any Publications by investigators, such materials will be subject to review by Mersana under this Section 7.5 only to the extent that Merck has the right to review such Publications, and Merck will use Commercially Reasonable Efforts to obtain such right. [***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.